Avacincaptad pegol, sold under the brand name Izervay, is a medication used for the treatment of age-related macular degeneration. Avacincaptad pegol is a complement inhibitor.
Avacincaptad pegol was approved for medical use in the United States in August 2023.
Avacincaptad pegol is indicated for the treatment of geographic atrophy secondary to age-related macular degeneration.
Avacincaptad pegol is the international nonproprietary name.